



Advances in Pathogenesis and Treatment of Colonic Diverticular Disease

Guest Editor:

Prof. Dr. Wolfgang Kruis

Clinic for Internal Medicine and Gastroenterology, Protestant Hospital Kalk, University of Cologne, Cologne, Germany

Deadline for manuscript submissions:
closed (30 June 2021)

Message from the Guest Editor

Diverticular disease of the colon (DDC) is a paradox. Its prevalence and the burden for patients and healthcare systems are steadily increasing, but scientific efforts need more support and intensified collaborative strategies. New insights into the genetic, molecular, and pathological background of the disease have emerged lately, but a conclusive pathogenetic model is still missing. Recommendations for treatments are changing accordingly. More insight into the pathogenesis, new targets of treatment, and more interdisciplinary discussion of controversial questions is urgently needed. The focus of Biomedicines is directed towards genetic mechanisms and molecular and pathological characteristics and their translation to medicine. Thus, a Special Issue of Biomedicines is very well adapted to foster the kind of information needed.

Keywords

- colonic diverticular disease
- diverticulitis
- pathogenesis
- diagnosis
- treatment





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)